Ocugen

MALVERN, PA · CIK 0001372299 · Biotech · Public

OCU400, a gene therapy for retinitis pigmentosa and inherited retinal disease

ocugen.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$126M
6 Form D · May 2020
77 months since last filing
Contracts
—
No federal contracts on record
Patents
28
6 granted · 22 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$34,300,000
Private capital raisedForm D · SEC$37,488,679
Private capital raisedForm D · SEC$10,323,988
Private capital raisedForm D · SEC$30,000,001
Private capital raised· 1 of 2 same dayForm D · SEC$395
Private capital raised· 2 of 2 same dayForm D · SEC$14,283,724
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2165NEMALIFE INC——
2166PRIME LABS INC——
2167Immunovant—$450M
2168Ocugen—$126M
2169VISIONARY PHARMACEUTICALS, INC.——
2170Excision BioTherapeutics Inc.—$71M
2171Context Therapeutics—$100M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 33 related persons
  • Kirk AndrianoExecutive Officer
  • Rasappa ArumughamExecutive Officer
  • Joshua BaltzellDirector
  • Kelly BeckExecutive Officer
  • Brian CallahanExecutive Officer
  • Kristen CastilloDirector
  • Prabhavathi FernandesDirector
  • Patrick FortuneDirector
  • David GillDirector
  • Peter GreenleafDirector · Executive Officer
  • Adam GridleyDirector · Executive Officer
  • John JohnsonDirector
  • Daniel JorgensenExecutive Officer
  • Uday KompellaDirector
  • Garheng KongDirector
  • Garheng Kong, M.D., Ph.DDirector
  • Garheng Kong, M.D., Ph.D.Director
  • Ramesh KumarDirector
  • Michael LewisDirector
  • Jonathan LieberDirector
  • Kevin McArdleExecutive Officer
  • Shankar MusunuriDirector · Executive Officer
  • Patrick O'DonnellDirector · Executive Officer
  • Manish PottiDirector
  • Philip PressDirector
  • Kevin RakinDirector
  • Dominic RedfernDirector
  • Harry ReinDirector
  • Sanjay SubramanianExecutive Officer
  • Vijay TammaraExecutive Officer
  • Laurence TarrantExecutive Officer
  • Suha TaspolatogluDirector
  • Junge ZhangDirector

Patents

USPTO · 6 granted of 28

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.